Bianchini Chiara, Ciorba Andrea, Pelucchi Stefano, Piva Roberta, Pastore Antonio
ENT Department, University Hospital of Ferrara, Ferrara, Italy.
Tumori. 2011 Mar-Apr;97(2):137-41. doi: 10.1177/030089161109700201.
This review focuses on recent advances in understanding the molecular mechanisms at the basis of cancer initiation and progression in the head and neck and also discusses the possible development of targeted cellular strategies. Intrinsic and acquired resistance of cancer cells to current conventional treatments, as well as recurrence, represent a major challenge in treating and curing the most aggressive and metastatic tumors also in the head and neck. Even though in some hematologic malignancies (i.e., non-Hodgkin's lymphomas) antibodies specifically designed to target tumor-specific cells have already been introduced, in solid tumors molecular targeted therapy is now entering clinical practice.
A PubMed database systematic review.
Molecular targeting could achieve specific damage to cancer cells, at the same time preserving functionally important tissues. This could offer new prospectives in primary and adjuvant treatment also of head and neck tumors.
本综述聚焦于对头颈部癌症发生和进展的分子机制的最新认识进展，并讨论靶向细胞策略的可能发展。癌细胞对当前传统治疗的内在和获得性耐药性以及复发，是治疗和治愈包括头颈部在内的最具侵袭性和转移性肿瘤的一大挑战。尽管在一些血液系统恶性肿瘤（如非霍奇金淋巴瘤）中，专门设计用于靶向肿瘤特异性细胞的抗体已经问世，但在实体瘤中，分子靶向治疗目前正进入临床实践。
对PubMed数据库进行系统综述。
分子靶向能够对癌细胞造成特异性损伤，同时保留功能重要的组织。这可能为头颈部肿瘤的一线治疗和辅助治疗提供新的前景。
